Sign In
Buy DYN
$25.18
-0.550 (-2.14%)
At Close: Jul 31, 2026
Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies
02:44pm, Friday, 14'th May 2021
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear
- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -
Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, followin
Edgewise Therapeutics Proposes Terms For $150 Million IPO
05:48pm, Tuesday, 23'rd Mar 2021
Edgewise Therapeutics has filed to raise $150 million in an IPO.
U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week
08:25am, Saturday, 13'th Mar 2021
The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
07:35am, Thursday, 04'th Mar 2021
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 -
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
07:25am, Thursday, 04'th Mar 2021
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
07:30am, Monday, 08'th Feb 2021
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
08:05pm, Wednesday, 20'th Jan 2021
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -
U.S. IPO Week Ahead: The IPO Market Braces For A September SNOWstorm In A 12-IPO Week
11:07am, Sunday, 13'th Sep 2020
The post-Labor Day IPO frenzy is here as 12 IPOs plan to raise $6.8 billion in the coming week, led by cloud data unicorn Snowflake.
IPO Update: Dyne Therapeutics Readies $175 Million IPO
04:23am, Sunday, 13'th Sep 2020
Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO.
Dyne Therapeutics Commences $100 Million IPO Plan
02:54am, Wednesday, 02'nd Sep 2020
Dyne Therapeutics has filed to raise capital in a U.S. IPO.
U.S. IPO Weekly Recap: The IPO Market Gears Up For Fall With Wave Of Filings In A 2 IPO Week
02:43pm, Sunday, 30'th Aug 2020
Two foreign electric vehicle makers and three SPACs went public this past week. A wave of filings brought 27 companies into the IPO pipeline.
Dynegy Donates $60,000 to Fund Critical COVID-19 Relief in Chicago Area
06:18pm, Thursday, 30'th Apr 2020
Dynegy today announced it is committing $60,000 to support the Chicago area, as individuals and households begin the process of economic recovery from COVID-19.
